412 related articles for article (PubMed ID: 22887127)
1. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer.
Nguyen HC; Xie W; Yang M; Hsieh CL; Drouin S; Lee GS; Kantoff PW
Prostate; 2013 Mar; 73(4):346-54. PubMed ID: 22887127
[TBL] [Abstract][Full Text] [Related]
2. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
Tinay I; Tan M; Gui B; Werner L; Kibel AS; Jia L
Prostate; 2018 Sep; 78(12):927-937. PubMed ID: 29748958
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
Cheng HH; Mitchell PS; Kroh EM; Dowell AE; Chéry L; Siddiqui J; Nelson PS; Vessella RL; Knudsen BS; Chinnaiyan AM; Pienta KJ; Morrissey C; Tewari M
PLoS One; 2013; 8(7):e69239. PubMed ID: 23935962
[TBL] [Abstract][Full Text] [Related]
4. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.
Watahiki A; Macfarlane RJ; Gleave ME; Crea F; Wang Y; Helgason CD; Chi KN
Int J Mol Sci; 2013 Apr; 14(4):7757-70. PubMed ID: 23574937
[TBL] [Abstract][Full Text] [Related]
5. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
Huang X; Yuan T; Liang M; Du M; Xia S; Dittmar R; Wang D; See W; Costello BA; Quevedo F; Tan W; Nandy D; Bevan GH; Longenbach S; Sun Z; Lu Y; Wang T; Thibodeau SN; Boardman L; Kohli M; Wang L
Eur Urol; 2015 Jan; 67(1):33-41. PubMed ID: 25129854
[TBL] [Abstract][Full Text] [Related]
6. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease.
Selth LA; Townley S; Gillis JL; Ochnik AM; Murti K; Macfarlane RJ; Chi KN; Marshall VR; Tilley WD; Butler LM
Int J Cancer; 2012 Aug; 131(3):652-61. PubMed ID: 22052531
[TBL] [Abstract][Full Text] [Related]
7. Combining PHI and miRNAs as Biomarkers in Prostate Cancer Diagnosis and Prognosis.
Ibrahim NH; Abdellateif MS; Thabet G; Kassem SH; El-Salam MA; El-Leithy AA; Selim MM
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307177
[TBL] [Abstract][Full Text] [Related]
8. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer.
Sun T; Yang M; Chen S; Balk S; Pomerantz M; Hsieh CL; Brown M; Lee GM; Kantoff PW
Prostate; 2012 Jul; 72(10):1093-103. PubMed ID: 22127852
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.
Rönnau CGH; Fussek S; Smit FP; Aalders TW; van Hooij O; Pinto PMC; Burchardt M; Schalken JA; Verhaegh GW
World J Urol; 2021 Oct; 39(10):3789-3797. PubMed ID: 33990872
[TBL] [Abstract][Full Text] [Related]
10. A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer.
Daniel R; Wu Q; Williams V; Clark G; Guruli G; Zehner Z
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28621736
[TBL] [Abstract][Full Text] [Related]
11. Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies.
Santos JI; Teixeira AL; Dias F; Maurício J; Lobo F; Morais A; Medeiros R
Tumour Biol; 2014 Jul; 35(7):7105-13. PubMed ID: 24760272
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers.
van Schooneveld E; Wouters MC; Van der Auwera I; Peeters DJ; Wildiers H; Van Dam PA; Vergote I; Vermeulen PB; Dirix LY; Van Laere SJ
Breast Cancer Res; 2012 Feb; 14(1):R34. PubMed ID: 22353773
[TBL] [Abstract][Full Text] [Related]
13. Activin A regulates microRNAs and gene expression in LNCaP cells.
Ottley EC; Nicholson HD; Gold EJ
Prostate; 2016 Aug; 76(11):951-63. PubMed ID: 27018851
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis.
Leite KR; Tomiyama A; Reis ST; Sousa-Canavez JM; Sañudo A; Camara-Lopes LH; Srougi M
Urol Oncol; 2013 Aug; 31(6):796-801. PubMed ID: 21880514
[TBL] [Abstract][Full Text] [Related]
15. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers.
Brunet Vega A; Pericay C; Moya I; Ferrer A; Dotor E; Pisa A; Casalots À; Serra-Aracil X; Oliva JC; Ruiz A; Saigí E
Oncol Rep; 2013 Jul; 30(1):320-6. PubMed ID: 23673725
[TBL] [Abstract][Full Text] [Related]
16. Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients.
He HC; Han ZD; Dai QS; Ling XH; Fu X; Lin ZY; Deng YH; Qin GQ; Cai C; Chen JH; Jiang FN; Liu X; Zhong WD
BMC Genomics; 2013 Nov; 14():757. PubMed ID: 24191917
[TBL] [Abstract][Full Text] [Related]
17. Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
[TBL] [Abstract][Full Text] [Related]
18. microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer.
Zedan AH; Hansen TF; Assenholt J; Pleckaitis M; Madsen JS; Osther PJS
Tumour Biol; 2018 May; 40(5):1010428318775864. PubMed ID: 29775158
[TBL] [Abstract][Full Text] [Related]
19. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG
Br J Cancer; 2014 May; 110(10):2462-71. PubMed ID: 24714754
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
